Preparing for a New Wave of mRNA Technologies

The ability of the biopharma industry to meet the worldwide demand for messenger RNA vaccines was facilitated by contract development and manufacturing organizations, which promptly adapted their facilities and capabilities specifically for vaccine production, offering contract fill/finish and cold chain services required to meet demand. Examining the lessons learned from the COVID-19 pandemic, this article provides a perspective on the strategies and tactics taken to deliver a better drug development program and highlights the importance of remembering key lessons as the industry moves toward an era of new drug modalities.

Read this article in BioPharm International’s May 2023 Partnerships for Outsourcing eBook.

About the author

Jeong Jin-hyeok is principal scientist in drug product at Samsung Biologics.

Article details

BioPharm International
eBook: Partnerships for Outsourcing
May 2023
Pages: 28–31

Citation

When referring to this article, please cite it as Jin-hyeok, J. Preparing for a New Wave of mRNA Technologies. BioPharm International’s Partnerships for Outsourcing eBook. May 2023.